Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Musculoskeletal pain - Pressure pain threshold |
Pressure pain threshold measured in rectus abdominis and lumbar muscles |
3 assessent times: T1(pre-intervention), T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Primary |
Musculoskeletal pain - quantitative Sensory Testing |
Quantitative sensory testing is a non-invasive technique used to assess and quantify sensory functions by determining sensation and pain thresholds using pressure. |
3 assessent times: T1(pre-intervention), T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Primary |
Musculoskeletal pain - pain drawing |
Identification of pain areas through a pain map: this consists of a human figure on a two-dimensional plane on which the patient can express the representation of the pain areas on a schematic of the body surface. |
3 assessent times: T1(pre-intervention), T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Primary |
Musculoskeletal pain - Central Sensitisation Inventory |
Central Sensitisation Inventory: is a self-report instrument that indirectly assesses somatic and emotional symptoms that have been found to be associated with Central Sensitisation. |
3 assessent times: T1(pre-intervention), T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Secondary |
Physical-Funcionality - Hand grip Strength |
Hand grip strength will be measured by the handgrip strength technique using a Jamar Plus+ digital hand dynamometer. |
3 assessent times: T1(pre-intervention), T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Secondary |
Physical-Funcionality - functional performance |
To assess functional performance patients will be instructed to cross their arms over their chest and complete as many standing cycles as possible in 30 s (30 second- Sit to stand). |
3 assessent times: T1(pre-intervention), T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Secondary |
Physical-Funcionality- Pelvic floor Dynamometry |
Dynamometry of the pelvic floor muscles: measurement of basal tone (g) and tone at maximum contraction (Phenix Liberty Dynamometer). |
3 assessent times: T1(pre-intervention), T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Secondary |
Physical-Funcionality - Body composition |
Body composition (% fat, % water, % muscle): record body composition (skeletal muscle mass and % body fat) with a bioimpedance scale (DC-430MA, Tanita Corporation of America, Inc, Arlignton Heights, IL, USA). |
3 assessent times: T1(pre-intervention), T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Secondary |
Physical-Funcionality - Motor control |
Determine motor control: clinical test of lumpopelvic and thoracolumbar dissociation will be used. |
assessent times: T1(pre-intervention), T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Secondary |
Physical-Funcionality - Lumbar spine flexibility |
Lumbar spine flexibility: It will be measured with the Schöber test |
assessent times: T1(pre-intervention), T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Secondary |
Physical-Funcionality - Catastrophyzing |
Catastrophyzing: to assess catastrophic thinking related to pain the Pain Catastrophyzing Scale (PCS) will be used |
assessent times: T1(pre-intervention), T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Secondary |
Physical-Funcionality - Kinesophobia |
Kinesophobia: it will be assessed with the Tampa Scale for Kinesophobia-11 (TSK-11), which consists of 11 items. |
assessent times: T1(pre-intervention), T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Secondary |
Quality of Life - Endometriosis |
Quality of life will be assessed using the Spanish version of the Endometriosis Health Profile-30 (EHP-30). |
assessent times: T1(pre-intervention), T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Secondary |
Quality of Life - Gastrointestinal |
Quality of life at the gastrointestinal level will be assessed using the Gastrointestinal Quality of Life Index, which addresses 5 domains (digestive symptoms, physical state, emotions, social dysfunction and effects of medical treatment). |
assessent times: T1(pre-intervention), T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Secondary |
Quality of Life - Sexual Function |
the abbreviated Index of Female Sexual Function (IFSF-6) will be used. It is a multidimensional self-reported instrument for the evaluation of female sexual function |
assessent times: T1(pre-intervention), T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Secondary |
Quality of Life - Stress |
Stress using the Perceived stress scale (PSQ). |
assessent times: T1(pre-intervention), T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Secondary |
Biomarkers - Inflamation |
Plasma markers of chronic inflammation and intestinal permeability will be assessed including a multiplex array of inflammation markers, and as specific markers of chronic inflammation associated with intestinal permeability, zonulin, C-reactive protein, Binding Protein , and bactericidal/permeability-increasing protein will be assessed. |
assessent times: T1(pre-intervention), T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Secondary |
Patient's satisfaction |
Satisfaction with the treatment received will be assessed using the Satisfaction with Treatment Received Scale (CRES-4). |
assessent times: T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Secondary |
Patient's perception of change |
Patient's Perception of change after the treatment will be measured by patients' global impression of change (PGIC) in a quantitative and qualitative way. |
assessent times: T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Secondary |
APP usability |
A questionnaire on the usability of the application will be used. System Usability Scale. |
assessent times: T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|
Secondary |
Adherence to treatment |
Adherence to treatment: in the experimental group it will be measured through the records made in the application https://fisiotrack.com/, in the control group it will be measured through an ad hoc activity diary that will be provided to them. |
assessent times: T2 (after 8 weeks intervention), T3 (after 16 weeks intervention) |
|